avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2013-0-1-60-63avk-177Research ArticleСИМПТОМАТОЛОГИЯ И ДИАГНОСТИКААЛКОГОЛЬНАЯ БОЛЕЗНЬ ПЕЧЕНИ. ЧАСТЬ 2АЛКОГОЛЬНАЯ БОЛЕЗНЬ ПЕЧЕНИ. ЧАСТЬ 2ЕреминаЕ. Ю.ЕреминаЕ. Ю.

кафедра пропедевтики внутренних болезней, директор гастроэнтерологического центра, г. Саранск

кафедра пропедевтики внутренних болезней, директор гастроэнтерологического центра, г. Саранск

eeu61@mail.ruФГБОУ ВПО «Мордовский государственный университет им. Н.П. Огарева»РоссияФГБОУ ВПО «Мордовский государственный университет им. Н.П. Огарева»Russian Federation201328022013016063Copyright © Еремина Е.Ю., 20132013Еремина Е.Ю.Еремина Е.Ю.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/177

В статье представлены современные данные о механизмах развития, основных клинических формах АБП и их лечении. Отмечены причины прогрессирования и основные факторы риска развития заболевания.

The article represents contemporary data on the illness development mechanisms, the main disease manifestation forms and the treatment methods of the alcoholic liver disease. It also covers the disease progression reasons and the main risk factors.

алкогольный стеатозгепатитциррозпатогенезклиникадиагностикалечениеalcoholic steatosishepatitiscirrhosispathogenyclinical picturediagnosticstreatmentReferencesАбдурахманов Д.Т. Алкогольный гепатит.// Клиническая гепатология. 2008. 4(2). С. 3–10.Абдурахманов Д.Т. Алкогольный гепатит.// Клиническая гепатология. 2008. 4(2). С. 3–10.Буеверов А.О., Павлов А.И., Ивашкин В.Т. Алкогольная болезнь печени: возможно ли улучшение прогноза?//Клинические перспективы гастроэнтерологии и гепатологии. 2011. № 2. С 3–10.Буеверов А.О., Павлов А.И., Ивашкин В.Т. Алкогольная болезнь печени: возможно ли улучшение прогноза?//Клинические перспективы гастроэнтерологии и гепатологии. 2011. № 2. С 3–10.Майер К.П. Гепатиты и последствия гепатита. М.: Гэотар, 2004. с. 720.Майер К.П. Гепатиты и последствия гепатита. М.: Гэотар, 2004. с. 720.Abittan C., Lieber C. Alcoholic liver disease. Clin. Perspect. in Gastroenterol. 1999; Sept.Oct.: 25763.Abittan C., Lieber C. Alcoholic liver disease. Clin. Perspect. in Gastroenterol. 1999; Sept.Oct.: 25763.Achord J.L. Review and treatment of alcoholic hepatitis: a metaanalysis adjusting for confounding variables. Gut 1995; 37: 1138.Achord J.L. Review and treatment of alcoholic hepatitis: a metaanalysis adjusting for confounding variables. Gut 1995; 37: 1138.Akriviadis E., Bolta R., Briggs W. Pentoxifylline improves short–term survival in severe acute alcoholic hepatitis: A double–blind, placebo–controlled trial. Gastroenterology, 2000, 119, 1637.Akriviadis E., Bolta R., Briggs W. Pentoxifylline improves short–term survival in severe acute alcoholic hepatitis: A double–blind, placebo–controlled trial. Gastroenterology, 2000, 119, 1637.Angelico M., Gandin C. Recombinant interferon-alpha and UDCA versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up Am. J.Gastroenterology 1995; 90: 263–269.Angelico M., Gandin C. Recombinant interferon-alpha and UDCA versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up Am. J.Gastroenterology 1995; 90: 263–269.Bosron W.F., Ehrig T., Li T.K. Genetic factors in alcohol metabolism and alcoholism. Sem Liver Dis 1993; 13: 26–38.Bosron W.F., Ehrig T., Li T.K. Genetic factors in alcohol metabolism and alcoholism. Sem Liver Dis 1993; 13: 26–38.Chen W., Liu Y., Glund C. Bile acids for viral hepatitis, 2003. Cochrane Database Syst Rev 2003; 2: CD 003181.Chen W., Liu Y., Glund C. Bile acids for viral hepatitis, 2003. Cochrane Database Syst Rev 2003; 2: CD 003181.Fabbri C., Marchetto S., Pezzoli A. et al. Efficacy of UDCA in association with alpha- interferon for chronic hepatitis C in alpha- interferon nonresponder patients. Eur. J. of Gastroenterol. Hepatol. 2000; 12 (5): 511–515.Fabbri C., Marchetto S., Pezzoli A. et al. Efficacy of UDCA in association with alpha- interferon for chronic hepatitis C in alpha- interferon nonresponder patients. Eur. J. of Gastroenterol. Hepatol. 2000; 12 (5): 511–515.Kono H., Rusyn I., Yin M. NADPH oxidase–derived free radicals are key oxidants in alcohol–induced liver disease. J Clin Invest, 2000; 106:867.Kono H., Rusyn I., Yin M. NADPH oxidase–derived free radicals are key oxidants in alcohol–induced liver disease. J Clin Invest, 2000; 106:867.Mioni D., Burra P., Pujatti A. et al. Carbohydrate deficient transferrin levels in alcohol abusers with and without severe liver disease. Gut 1997; 43(1):181.Mioni D., Burra P., Pujatti A. et al. Carbohydrate deficient transferrin levels in alcohol abusers with and without severe liver disease. Gut 1997; 43(1):181.O’Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease. Hepatology, 2010, 51, 307–328.O’Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease. Hepatology, 2010, 51, 307–328.Plevris J.N., Hayes P.C., Bouchier I.A.D. Ursodeoxycholic acid in the treatment of alcoholic liver disease. Eur J Gastroenterol Hepatol 1991; 3: 65–36.Plevris J.N., Hayes P.C., Bouchier I.A.D. Ursodeoxycholic acid in the treatment of alcoholic liver disease. Eur J Gastroenterol Hepatol 1991; 3: 65–36.Rolla R., Vay D., Mottaran E. Detection of circulating antibodies against malondialdehyde–acetaldehyde adducts in patients with alcohol–induced liver disease. Hepatology, 2000; 31: 878.Rolla R., Vay D., Mottaran E. Detection of circulating antibodies against malondialdehyde–acetaldehyde adducts in patients with alcohol–induced liver disease. Hepatology, 2000; 31: 878.Wheeler M. Ethanol and HCV–induced cytotoxicity: the perfect storm. Gastroenterology, 2005, 128, 232–4.Wheeler M. Ethanol and HCV–induced cytotoxicity: the perfect storm. Gastroenterology, 2005, 128, 232–4.

The authors declare that there are no conflicts of interest present.